Comprehensive viral screening panel: to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses as well as other rapidly emerging viruses that…
Ended Awarded Last action
- Contract number
- 75N93021F00002
- Awardee
-
Utah State University UEI SPE2YDWHDYU4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $515,088
Award facts
- Opportunity
-
- B07 Solicitation number
- Contract value 77% obligated
-
- $515,088.00 Current, with exercised options
- $669,786.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Logan, UT 84322, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$37,135 | |
| Original award | $552,223 |
About this award
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded Utah State University a $669,786 firm fixed price delivery order against the In Vitro Assessments of Antimicrobial Activity master IDIQ contract. USU will perform a comprehensive viral screening panel under this award to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses as well as other rapidly emerging viruses that utilize the same assay methodology. The work will be conducted in Logan, Utah over a one year period ending in August 2022. No subcontractors or set aside designations were identified. This delivery order provides NIAID funding for USU to assess potential antiviral therapeutics in support of the institute's infectious disease research programs.
Description
Comprehensive viral screening panel: to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses as well as other rapidly emerging viruses that utilize the same assay methodology.
Quick answers
Who was awarded contract 75N93021F00002?
75N93021F00002 was awarded to Utah State University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 11, 2021.
How much is contract 75N93021F00002 worth?
The government has obligated $515,088 on 75N93021F00002. Its potential value, with all options, is $669,786.
Is contract 75N93021F00002 an order under another contract?
Yes. 75N93021F00002 is a delivery order under 75N93019D00021, an indefinite delivery contract, on In Vitro Assessments of Antimicrobial Activity (IVAAA).
Was contract 75N93021F00002 competed?
The extent of competition for 75N93021F00002 was full and open competition. The government received 4 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award